Oral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands: results from the ATHENA cohort, 2018 to 2022 (Q28805): Difference between revisions
Jump to navigation
Jump to search
Superraptor (talk | contribs) (Added [en] alias: Oral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands) |
Superraptor (talk | contribs) (Changed claim: author (P72): Casper Rokx (Q28791)) |
||||||
| Property / author: Casper Rokx / qualifier | |||||||
| Property / author: Casper Rokx / qualifier | |||||||
| Property / author: Casper Rokx / qualifier | |||||||
series ordinal: 5
| |||||||
| Property / author: Casper Rokx / qualifier | |||||||
| Property / author: Casper Rokx / qualifier | |||||||
| |||||||
Revision as of 19:26, 5 November 2024
No description defined
- Oral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands: results from the ATHENA cohort, 2018 to 2022.
- Oral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Oral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands: results from the ATHENA cohort, 2018 to 2022 |
No description defined |
|
Statements
BackgroundIn the Netherlands, HIV pre-exposure prophylaxis (PrEP) has been available since 2019. (English)
However, the extent of PrEP use prior to HIV diagnosis and development of PrEP-resistance-associated mutations (RAMs) is not known.AimWe assessed prior PrEP use and potential transmission of PrEP RAMs among men who have sex with men (MSM) and transgender persons (TGP) with a new HIV diagnosis in the Netherlands.MethodsData on prior PrEP use between 1 January 2018 and 31 December 2022 were [...] (English)
We assessed proportion of prior PrEP use, detected PrEP associated RAMs and assessed potential onward transmission of RAMs between 2010 and 2022 using a maximum likelihood tree.ResultsData on prior PrEP use were available for 583/1,552 (36.3%) individuals, with 16% (94/583) reporting prior PrEP use. (English)
In 489 individuals reporting no prior PrEP use, 51.5% did not use PrEP due to: low HIV-risk perception (29%), no access (19.1%), personal preference (13.1%), and being unaware of PrEP (19.1%). (English)
For PrEP users, 13/94 (13.8%) harboured a M184V/I mutation, of whom two also harboured a K65R mutation. (English)
In people with a recent HIV infection, detection of PrEP RAMs increased from 0.23% (2/862) before 2019 to 4.11% (9/219) from 2019. (English)
We found no evidence of onward transmission of PrEP RAMs.ConclusionThe prevalence of PrEP-associated RAMs has increased since PrEP became available in the Netherlands. (English)
More widespread access to PrEP and retaining people in PrEP programmes when still at substantial risk is crucial to preventing new HIV infections. (English)
Vita W (English)
Jongen (English)
VW
Daniela (English)
Bezemer (English)
D
Ard (English)
van Sighem (English)
A
Anders (English)
Boyd (English)
A
Casper (English)
Rokx (English)
C
Karin (English)
Grintjes (English)
K
Aafke (English)
Cents-Bosma (English)
A
Eline (English)
Op de Coul (English)
E
Birgit (English)
van Benthem (English)
B
Annemarie (English)
Wensing (English)
A
Ferdinand Wnm (English)
Wit (English)
FW
Marc (English)
van der Valk (English)
M
Q28804 (Deleted Item)
ATHENA national observational HIV cohort (English)
19 October 2024
20 September 2024
<b>Conflict of interest:</b> AB received speaker’s fees from Gilead Sciences. (English)
MvdV received unrestricted research grants and fees for participation in advisory boards from Gilead Sciences, MSD and ViiV, all paid to his institution. (English)
AMJ has received unrestricted research grants and fees for participation in advisory boards from Gilead Sciences and Viiv/GSK paid to her institution. (English)
CR received unrestricted research grants and fees for advisory boards from Gilead Sciences and ViiV Healthcare. (English)
FW received fees for advisory boards from Gilead Sciences and ViiV Healthcare. (English)
All other authors declare no competing interest. (English)